Tumor necrosis factor α release is a major biological event associated with rituximab treatment

Hematology Journal

Volumn 2, Issue 6, 2001, Pages 378-384

  Bienvenu, J ^a   Chvetzoff, R ^a   Salles, G ^a   Balter, C ^a   Tilly, H ^a   Herbrecht, R ^a   Morel, P ^a   Lederlin, P ^a   Solal Celigny, P ^a   Audhuy, B ^a   Christian, B ^a   Gabarre, J ^a   Casasnovas, O ^a   Marit, G ^a   Sebban, C ^a   Coiffier, B ^a  

^a Institut d'Hématologie   (France)

Author keywords

CHOP; Cytokines; DLCL; Rituximab; TNF

Indexed keywords

COMPLEMENT; COMPLEMENT COMPONENT C3A; CYCLOPHOSPHAMIDE; CYTOKINE; DEXCHLORPHENIRAMINE; DOXORUBICIN; LACTATE DEHYDROGENASE; PARACETAMOL; PREDNISONE; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA; VINCRISTINE;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; CHILL; CLINICAL TRIAL; COMPLEMENT ACTIVATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION FUNCTION; CYTOKINE RELEASE; CYTOLYSIS; DEMOGRAPHY; DISEASE SEVERITY; DRUG INFUSION; FEVER; HUMAN; LEUKOCYTE COUNT; LUNG EDEMA; LYMPHOCYTE; MAJOR CLINICAL STUDY; MONOCYTE; NEUTROPHIL; NONHODGKIN LYMPHOMA; PARAMETER; RANDOMIZED CONTROLLED TRIAL; RIGOR; SIDE EFFECT; STATISTICAL ANALYSIS;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; B-LYMPHOCYTES; BLOOD CELL COUNT; COMPLEMENT ACTIVATION; COMPLEMENT C3A; HUMANS; KINETICS; L-LACTATE DEHYDROGENASE; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL, DIFFUSE; MIDDLE AGED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0035677256     PISSN: 14664860     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.thj.6200133     Document Type: Article

References (15)

1. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma
2. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma
3. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
4. CHOP plus rituximab chemoimmunotherapy of indolent B-cell lymphoma
5. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma. A multicenter phase II study
6. Treatment of mantle cell lymphoma with rituximab (chimeric monoclonal anti-CD20 antibody): Analysis of factors associated with response
7. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells
8. IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma
9. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: Association with increased infusion-related side effects and rapid blood tumor clearance
10. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an Anti-CD20 monoclonal antibody (Rituximab, IDEC-C2B8)
11. MabThera (rituximab) plus CHOP is superior to CHOP alone in elderly patients with diffuse large B-cell lymphoma: Interim results of a randomized GELA trial
12. Tumor necrosis factor ligand-receptor system can predict treatment outcome in lymphoma patients
13. Elevated circulating levels of TNF-alpha and its p55 soluble receptor are associated with an adverse prognosis in lymphoma patients
14. Complement activation during OKT3 treatment: A possible explanation for respiratory side effects
15. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets